5 Overlooked Penny Stocks to Buy Right Now

3. Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX)

Number of Hedge Fund Holders: 20

Upside Potential: 275.72%

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX), backed by significant analyst-implied upside, ranks among the overlooked penny stocks to buy right now. An expanding radiopharmaceutical pipeline, now stretching into a new brain tumor indication, is strengthening the company’s long-term growth narrative.

On July 1, 2026, Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) updated its corporate presentation to highlight progress across its 212Pb-based radiopharmaceutical pipeline and its integrated manufacturing strategy. The update emphasized the company’s theranostic approach targeting solid tumors with next-generation alpha therapies, along with plans to expand its addressable market through regional daily production and direct-to-hospital delivery. The presentation provided material related to multiple ongoing Phase 1/2a trials, including VMT-α-NET for SSTR2-positive neuroendocrine tumors, VMT01 for melanoma, and PSV359 for FAP-α-expressing solid tumors, with early data pointing to deepening and durable responses, favorable safety and tolerability, and improved tumor retention.

That update followed news on June 3, 2026, that Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) dosed the first meningioma patient with [212Pb]VMT-α-NET in its ongoing Phase 1/2a study. The new cohort is designed to evaluate safety, dosimetry and preliminary anti-tumor activity in meningioma, expanding the company’s strategy of testing VMT-α-NET across somatostatin receptor subtype 2 (SSTR2)-expressing tumor types beyond neuroendocrine tumors. Meningiomas represent roughly 40% of primary central nervous system tumors diagnosed annually in the United States, and consistently express SSTR2, supporting their role as a target for this class of therapy.

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies (TATs) for cancer using the isotope Pb-212. Its theranostic approach combines imaging (Pb-203) with therapy (Pb-212) to deliver targeted radiation directly to tumors, minimizing damage to healthy tissue, with active trials for neuroendocrine tumors and melanoma.